NEOPLASMS BY SITE

This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can help some patients with stage II-IIIa bladder cancer avoid bladder removal. About 90 participants will receive either one or both drugs, and doctors will check if the cancer disa…

This study tests a drug called alectinib, already approved for some lung cancers, in people with other rare cancers that have a specific gene change (ALK). About 30 adults, teens, and children will receive the drug to see if it shrinks tumors or stops cancer growth for at least 2…

This study tests a new drug called pocenbrodib, either alone or with other treatments, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels. A…

This study tests a new medicine (PF-08634404) combined with standard chemotherapy against an approved drug (bevacizumab) plus chemotherapy for people with colorectal cancer that has spread. About 800 adults who have not had prior treatment for metastatic disease will be randomly …

This early-stage trial tests a specially engineered virus, G207, in children and young adults (ages 3 to 21) whose cerebellar brain tumors have come back or not responded to standard treatments. The virus is injected directly into the tumor, and a single low dose of radiation is …

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB), high microsatellite instability (MSI), or a specific DNA repair defect (CMMRD). About 30 adults, teens, and children will receive the…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. About 73 adults are being…

This study tests a drug called entrectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change (ROS1 fusion). About 30 adults and children with these rare tumors will receive the drug. Researchers will measure if tumors shrink …

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with other rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if their tumors shrink or stop growing for at least 24 weeks. The goal is to fi…